Testoluten

ExperimentalKhavinson bioregulator / researchExperimental

Also known as: Testicular bioregulator

Peptide preparation derived from testicular tissue and sold as a male endocrine bioregulator in the Khavinson tradition. It is a complex of low-molecular-weight peptides rather than a single defined molecule, and is distinct from Testagen, the synthetic tetrapeptide associated with the same tissue. It is not a treatment for hypogonadism or a substitute for testosterone therapy, and it is not FDA-approved. No study of Testoluten itself is indexed in PubMed; the studies cited here are class-level work on short peptide bioregulators.

Calculate Dose

For research use only.

Key Facts

CAS
—
Molecular Weight (MW)
—
Half-life
Not established
FDA status
Not Approved
Evidence level
Insufficient Evidence
Human dose established
No
Administration Route
Not established in humans
Frequency
Not established in humans
Last updated
Nov 7, 2026
Reviewed
Nov 7, 2026
Targets
Testis (proposed)

Vendor price snapshot

None of these listings has a price per mg to compare. From public vendor listings; confirm the live price on the vendor site. Peptide Library does not sell peptides.

Vendors listing this peptide
1
Listed offers
2
Price per mg
—

Open calculator · Compare vendors

Research summary

Peptide preparation derived from testicular tissue and sold as a male endocrine bioregulator in the Khavinson tradition. It is a complex of low-molecular-weight peptides rather than a single defined molecule, and is distinct from Testagen, the synthetic tetrapeptide associated with the same tissue. It is not a treatment for hypogonadism or a substitute for testosterone therapy, and it is not FDA-approved. No study of Testoluten itself is indexed in PubMed; the studies cited here are class-level work on short peptide bioregulators.

Research evidence

  • Regulatory review (FDA label)None in reviewed sources
  • Controlled human trialsNone in reviewed sources
  • Early or uncontrolled human studiesNone in reviewed sources
  • Lab & animal studiesNone in reviewed sources
How it works

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

Peptide Library's Testoluten profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.

Testoluten dosage: no established human dose

Testoluten has no established human dosage. It is sold as oral capsules described as a testis peptide bioregulator. No study of Testoluten is indexed in PubMed under that name, and no trial is registered on ClinicalTrials.gov. The only related evidence is laboratory work on other peptides from the same Russian research tradition.

Insufficient Evidence

No established human dosage.

Human clinical evidence: None identified.

Preclinical research: Testoluten is marketed in the Khavinson bioregulator tradition as a peptide complex from testis tissue. Its composition is not published in an indexed source, so it cannot be matched to any studied peptide. The series literature comes mostly from one research group in Russian-language journals. No animal or human study of Testoluten itself could be found, so nothing here establishes a human dose, route or interval.

Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.

Dosage evidence summary for Testoluten
Human dosing establishedNo
RouteNot established in humans
Evidence levelInsufficient Evidence
Last reviewed2026-11-07

Preclinical and analog research

Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.

Research-reported dosing for Testoluten, one row per studied regimen
Study / contextPopulationDoseRouteFrequencyDurationOutcome studiedSource
Class-level (analog evidence) — other Khavinson peptides in rat tissue explants (2001)Preclinical · Cell and tissue culture study of related synthetic peptides (analog evidence)Studied an analog, not Testoluten itselfExplants of rat brain cortex, subcortical structures, liver and thymus in organotypic cultureNot stated in the indexed abstract; tested in tissue culture, not given to an animal or a personIn vitro, added to culture——Cortagen, Epithalon, Livagen and Vilon each stimulated growth of explants from the tissue their source peptide complex came from. No testis tissue or testis peptide was tested in this study.Tissue-specific effects of peptides. Bull Exp Biol Med. 2001.

Where sources disagree

  • No indexed study or registered trial reports a dose of Testoluten, so intake directions given for it have no verifiable primary source.
  • Testoluten and Testagen (Lys-Glu-Asp-Gly) are both linked to the testis by sellers but are different products; the Testagen profile covers the synthetic peptide.
  • Testoluten is not a treatment for low testosterone and no study has measured a hormone outcome after giving it.
  • Evidence for other Khavinson peptides or extracts is not evidence for this product. Each peptide or extract in the series is a different preparation.

Sequence & molecular data

Sequence and molecular data for Testoluten
Half-lifeNot established
AppearanceWhite lyophilized powder
FormulationLyophilized Powder

Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.

Science

Mechanism of Action

Testoluten is a peptide preparation derived from testicular tissue and marketed in the Khavinson tradition. Like other natural preparations in the series it is a complex of low-molecular-weight peptides rather than a single characterised molecule, so no sequence, receptor or signalling pathway can be assigned, and it is distinct from Testagen, the synthetic tetrapeptide associated with the same tissue. The proposed mechanism follows the series hypothesis of tissue-preferential gene regulation. There is no controlled human evidence, and it is not a treatment for any endocrine condition.

Origin

Peptide preparation from testicular tissue (per its description).

Targets

Testis (proposed)

Regulatory & research status

Testoluten is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

Regulatory and research status for Testoluten
FDA statusNot Approved
AvailabilityResearch-Only
WADA (sport)Unknown / Not Listed
Library classificationResearch-Only

How FDA approval, compounding and research-only status differ

Benefits

Historical category

Testoluten side effects

Testoluten has no controlled human safety data. The effects below are reported, not established, and absence from the list is not evidence of safety.

Side Effects

  • Not characterized

Storage & stability

This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.

Testoluten: frequently asked questions

What is Testoluten?

Peptide preparation derived from testicular tissue and sold as a male endocrine bioregulator in the Khavinson tradition. It is a complex of low-molecular-weight peptides rather than a single defined molecule, and is distinct from Testagen, the synthetic tetrapeptide associated with the same tissue. It is not a treatment for hypogonadism or a substitute for testosterone therapy, and it is not FDA-approved. No study of Testoluten itself is indexed in PubMed; the studies cited here are class-level work on short peptide bioregulators.

How does Testoluten work?

Testoluten is a peptide preparation derived from testicular tissue and marketed in the Khavinson tradition. Like other natural preparations in the series it is a complex of low-molecular-weight peptides rather than a single characterised molecule, so no sequence, receptor or signalling pathway can be assigned, and it is distinct from Testagen, the synthetic tetrapeptide associated with the same tissue.

Is Testoluten FDA approved?

No. Testoluten is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

What peptides are similar to Testoluten?

Compounds most often compared with Testoluten include Bonomarlot, Bronchogen, Cardiogen and Cartalax. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

References

Related research, comparisons & guides

Related peptides

Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 4

This Testoluten profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error

Track Testoluten research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →